GCM
RYTM icon

Graham Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Graham Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,436
Closed -$1.15M – 1321
2024
Q1 		$1.15M Buy
+26,436
New +$1.16M 0.02% 388

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Graham Capital Management's RYTM Position: Q2 2024 in Review

Graham Capital Management sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2024, closing a stake of 26,436 shares — an estimated $1.15M sold.

Graham Capital Management first reported a position in RYTM in Q1 2024 and held it in 1 quarter. The position peaked at $1.15M in Q1 2024. 165 funds tracked by Wall St. Rank hold RYTM as of Q2 2024.

  • Graham Capital Management reported no remaining Rhythm Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Graham Capital Management sold 26,436 Rhythm Pharmaceuticals shares in Q2 2024, an estimated $1.15M.
  • Graham Capital Management first reported a position in Rhythm Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Graham Capital Management's Rhythm Pharmaceuticals position peaked at $1.15M in Q1 2024.
  • 165 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2024.

Based on Graham Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.